ARDX
Ardelyx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARDX
Ardelyx, Inc.
A biopharmaceutical company that develops small molecule therapeutics for the treatment of cardio-renal, gastrointestinal
400 Fifth Ave., Suite 210, Waltham, Massachusetts 02451
--
Ardelyx, Inc., is a clinical-stage biopharmaceutical company dedicated to the discovery, commercialization of innovative development, non-systematic small molecule drug therapy work, specializing in the gastrointestinal aspects, the treatment of heart and kidney, gastrointestinal and metabolic diseases. The company's developed drug discovery and design platform enables it to discover and design new drug candidates in a fast and cost-effective way. Founded in Delaware on October 17, 2007, the company changed its name from nteryx to ardelyx in June 2008.
Earnings Call
Q1/2025
Estimate EPS-0.08
Actual EPS-0.17
Estimate Revenue79.44M
Actual Revenue74.11M
Ardelyx's Q1 2025 Earnings Call: Unpacking Key Contradictions in Financial Projections and Market Dynamics
May 02,2025 07:32
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.14
Actual EPS-0.08
Estimate Revenue81.08M
Actual Revenue97.66M
Ardelyx's Q2 2025 Earnings Call: Key Contradictions in XPHOZAH and IBSRELA Growth Strategies
Aug 04,2025 08:20
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ARDX has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected -0.07, beating expectations. The chart below visualizes how ARDX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARDX has released its 2025 Q3 earnings report, with revenue of 110.33M, reflecting a YoY change of 12.30%, and net profit of -969.00K, showing a YoY change of -19.78%. The Sankey diagram below clearly presents ARDX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
